parthenolide has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, RT; Idris, AI; Logan, JG; Marino, S; Mollat, P | 1 |
| Eliseev, RA; Giang, AH; O'Keefe, R; Rosier, R; Schwarz, E; Shapovalov, Y; Zuch, D | 1 |
2 other study(ies) available for parthenolide and Bone Cancer
| Article | Year |
|---|---|
Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Topics: Animals; Apoptosis; beta Catenin; Bone Neoplasms; Breast Neoplasms; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Osteoblasts; Osteoclasts; Osteogenesis; Osteolysis; Sesquiterpenes; Signal Transduction; Time Factors | 2017 |
Targeting radioresistant osteosarcoma cells with parthenolide.
Topics: Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Neoplastic Stem Cells; NF-kappa B; Osteosarcoma; Radiation Tolerance; Radiation, Ionizing; Reactive Oxygen Species; Sesquiterpenes | 2012 |